NRx Pharmaceuticals, Inc. announced submission an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of NRX-101 to treat Chronic Pain. The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycl closerine in the treatment of pain. Nonclinical and substantial clinical data are already on file with FDA for NRX-101, which has already been granted Breakthrough Therapy Designation for the treatment of suicidal Bipolar Depression.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | +12.74% | +16.45% | -23.04% |
Apr. 18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
Apr. 18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.04% | 36.89M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain